MA11.068g, Sentinel Lymph Node Biopsy and Mapping
Independence Blue Cross Medicare Advantage policy MA11.068g has been expanded to add cervical cancer as a medically necessary indication for sentinel lymph node biopsy (SLNB) and mapping, effective April 20, 2026. Billing teams must ensure cervical cancer cases are now recognized as covered rather than experimental/investigational, and verify proper documentation and coding are in place for these procedures.